Refractory Tumors Completed Phase 1 / 2 Trials for Denosumab (DB06643)

Also known as: Refractory Tumor

IndicationStatusPhase
DBCOND0036368 (Refractory Tumors)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03415477Denosumab: A Potential Treatment Option for Aneurysmal Bone CystsTreatment